Biodistribution of 111In-labelled SCN-bz-DTPA-BC-2 MAb following logo-regional injection into glioblastomas

International Journal of Cancer

Volumn 71, Issue 5, 1997, Pages 810-816

  Merlo, Adrian ^a,c   Jermann, Eduard ^a   Hausmann, Oliver ^a   Chiquet Ehrismann, Ruth ^b   Probst, Alphonse ^a   Landolt, Hans ^a   Maecke, Helmut R ^a   Mueller Brand, Jan ^a   Gratzl, Otmar ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^c Neurologische Universitatsklinik Basel   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY IN 111; PENTETIC ACID; TENASCIN ANTIBODY; UNCLASSIFIED DRUG; INDIUM; MONOCLONAL ANTIBODY; TENASCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; GLIOBLASTOMA; HUMAN; INTRATUMORAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; BAGG ALBINO MOUSE; BRAIN TUMOR; IMMUNOLOGY; KINETICS; METABOLISM; MIDDLE AGED; MOUSE; TISSUE DISTRIBUTION;

AGED; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; INDIUM RADIOISOTOPES; KINETICS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; TENASCIN; TISSUE DISTRIBUTION;

EID: 0030612408     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970529)71:5<810::AID-IJC19>3.0.CO;2-B     Document Type: Article

References (23)

1. BLACK, P.M., Brain tumors. New Engl. J. Med., 324, 1555-1564 (1991).
2. 125I-EGF-425 in patients with brain tumors: preliminary results of a phase-II clinical trial. Antibody Imnuinoconj. Radiopharm., 3, 169-179 (1990).
3. BRECHBIEL, M.W., GANSOW, O.A., ATCHER, R.W., SCHLOM, J., ESTEBAN, J., SIMPSON, D.E. and COLCHER, D., Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labelling and tumor-imaging studies. Inorg. Chem., 25, 2772-2781 (1986).
4. CARRASQUILLO, J., Imaging and dosimetry determinations using radiolabeled antibodies. In: S.T. Rosen and T.M. Kuzel (eds.), Imnnwoconjugate therapy of hematologic malignancies, pp. 65-97. Kluwer Academic Publishers. Dordrecht (1993).
5. CHIQUET-EHRISMANN, R., Tenascins, a growing family of extracellular matrix proteins. Experientia. 51, 853-862 (1995).
6. GRIFFITHS, G.L., Radiochemistry of therapeutic radinnuclides. In: D.M. Goldenberg (ed.). Cancer therapy with nidiolabeled antibodies, pp. 115-140, CRC Press. London, New York (1995).
7. HIGUCHI, M., OHNISHI, T., ARITA, N., HIRAGA, S. and HAYAKAWAKA, T., Expression of tenascin in human gliomas: its relation to histological malianancy. tumor differentiation and ansioaenesis. Acta Neuropathol., 85, 481-487 (1993).
8. JAIN, R.K., Physiological resistance to the treatment of solid tumors. In: B.A. Teicher (ed.). Drug resistance in oncology, pp. 87-105, Marcel Dekker, New York, Basel, Hong Kong (1993).
9. 131]anti-B1 (anti-CD20) antibody. New Engl. J. Med., 329, 459-466 (1993).
10. KÖHLER, G. and MILSTEIN, C., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (Lond.), 256, 495-497 (1975).
11. MEARES, C.F., MCCALL, M.J., REARDAN, D.T., GODDWIN, D.A., DIAMANTI, C.I. and MCTIGUE, M., Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis and subsequent addition of metal ions. Anal. Biochem., 142, 68-78 (1984).
12. NATALI, P.G., NICOTRA, M.R., BIGOTTI, A., BORRI, C., CASTELLANI, P. RISSO, A.M. and ZARDI, L., Comparative analysis of the expression of the extracellular-matrix protein tenascin in normal and human fetal, adult and tumor tissues. Int. J. Cancer, 47, 811-816 (1991).
13. PAPANASTASSIOU, V., PIZER, B.L., COAKHAM, H.B., BULLIMORE, J., ZANARIRI, T. and KEMSHEAD, J.T., Treatment of recurrent and cystic malignant glioma by a single intracavity injection of 1-131 monoclonal antibody: feasibility, pharmacokinetics and dosimetry. Brit. J. Cancer, 67, 144-151 (1993).
14. PATEL, K., ROSSELL, R.J., BOURNE, S., MOORE, S.E., WALSH, F.S. and KEMSHEAD, J.T., Monoclonal antibody UJ13A recognises the neural-cell adhesion molecule (NCAM). Int. J. Cancer, 44, 1062-1068 (1989).
15. PRESS, O.W. and 12 OTHERS, Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone-marrow support. New Engl. J. Med., 329, 1219-1224 (1993).
16. 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res., 55, 5952s-5956s (1995).
17. RUSER, G., Synthese und Evaluation bifunktioneller Liganden für das "matched pair" Indium-III/Yttrium-90. Markierungen von monoklonalen Antikörpern und Peptidhormonen. Universität Basel (1993).
18. SHARKEV, R.M., BLUMENTHAL, R.D. and GOLDENBERG, D.M., Development of cancer radioimmunotherapy and its potential use as an adjuvant treatment. In: D.M. Goldenbera (ed.), Cancer therapy with radioiabeled antibodies, pp. 115-140, CRC Press, London. New York (1995).
19. SIRI, A., CARNEMOLLA, B., SAGINATT, M., LEPRINI, A., CASARI, G., BARALLE, F. and ZARDI, L., Human tenascin: primary structure. pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies. Nucleic Acids. Res., 19, 525-531 (1991).
20. STEWART, J.S.W. and 13 OTHERS. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J. Clin. Oncol., 8, 1941-1950 (1990).
21. WESTLIN, J.E., SNOOK, D., NILSSON, S., HUSIN, S., ENBLAD, P., STAVROU, S., EPENETOS, A.A. and BERGH, J., Intravenous and intratumoural therapy of patients with malignant gliomas with "Yttrium-labelled monoclonal antibody MUC 2-63. In: A. Epenetos (ed.). Monoclonal antibodies: applications in clinical oncology, pp. 17-25. Chapman and Hall Medica. London (1992).
22. 2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res., 50, 4105-4110 (1990).
23. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res., 49, 2807-2813 (1989).